News

NCX 434 is a nitric oxide (NO)-donating new molecular entity (NME) and a potential preclinical candidate in diabetic macular edema (DME). NicOx’s new preclinical study demonstrated that NCX

Mymetics’ scientists, in collaboration with the Molecular Virology department of the University of Groningen, found that two consecutive injections of the vaccine at a two-week interval successfully protected

Under the terms of the agreement, Gilead will acquire CGI for up to $120m, the majority as an upfront payment and the remaining based on clinical development progress,

Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, is a once-daily oral treatment in type 2 diabetes. Boehringer Ingelheim said that the results of the trial were presented at the

Kowa and Abbott said that with the current agreement Pitavastatin will now be marketed in five continents. Reportedly, Abbott is now expected to apply for regulatory approvals to

MannKind said that Afrezza is a drug-device combination product, consisting of Afrezza inhalation powder pre-metered into single use dose cartridges and the light, discreet and easy-to-use Afrezza Inhaler.

P&G said that the recalling is part of the precautionary step the company is taking after finding that the child-resistant cap does not work in a small percentage

Sanofi-aventis and Metabolex said that GPR119 receptor agonists (or G-protein coupled receptor 119) are known to exert the effects on glucose metabolism by a dual mode of action

TRL started its new operations in May by appointing three new executives, Masaki Yamada as CEO, Toshihiro Hosaka as senior vice president and Roland Newman as VP and